October 18, 2024 11:25 AM EDTUpdated 01:11 PM
R&D
Pharma
FDA+

FDA par­tial­ly holds BioN­Tech's Phase 3 an­ti-CT­LA-4, com­pa­ny paus­es en­roll­ment

Kyle LaHucik

Senior Reporter

The FDA put a par­tial clin­i­cal hold on a Phase 3 tri­al of an an­ti-CT­LA-4 an­ti­body from On­coC4 and its part­ner BioN­Tech, the Ger­man biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times